Novocure to present final results from pivotal Phase 3 METIS trial at ASTRO

Novocure (NVCR) “announced that final results from the Phase 3 METIS trial of Tumor Treating Fields therapy for brain metastases from non-small cell lung cancer, NSCLC, will be presented today at the 2025 American Society for Radiation Oncology Annual Meeting taking place September 27 – October 1 in San Francisco and simultaneously published in the International Journal of Radiation Oncology Biology and Physics. The METIS trial evaluated the use of TTFields therapy and best supportive care to treat adult patients with 1-10 newly diagnosed brain metastases from NSCLC following stereotactic radiosurgery compared to BSC alone. The trial met its primary endpoint, showing a statistically significant delay in time to first intracranial progression for patients who received TTFields therapy and BSC compared to patients receiving BSC alone.”